ERBB2 and breast cancer: Hence, we speculate that trastuzumab-resistant ER+ Her2-positive BC acquires mutations that impair DNA damage repair while trastuzumab-resistant ER− Her2-positive tumors acquire mutations that enhance mitotic signaling.